Novo Nordisk Q4 Profit Beats Expectations, Sees Slower Growth in 2025
LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen investor concerns that the company is losing its edge in the competitive obesity market to rival Eli Lilly.
ConocoPhillips beat Wall Street estimates for fourth-quarter profit on Thursday, with higher production helping offset lower ...
The fourth-quarter results highlighted Linde’s capability to manage costs effectively, as its adjusted operating profit ...
Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The ...
Societe Generale said on Thursday it had doubled fourth-quarter profits after a recovery in its retail bank and increased ...
Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Shares of the banking giant UBS Group AG (UBS) dropped nearly 6% in pre-market trading, despite reporting strong Q4 profits.
Ford Motor on Wednesday projected up to $5.5 billion in losses on its electric vehicle and software operations this year, a ...
Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...
ConocoPhillips reported better-than-expected fourth-quarter earnings and announced plans to return more than $1 billion to ...
(BKH) on Wednesday reported fourth-quarter earnings of $98.1 million. On a per-share basis, the Rapid City, South Dakota-based company said it had profit of $1.37. The energy company posted revenue of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback